Parainfluenza Virus Infection Market Is Expected to surge During the Forecast Period (2019-2032), DelveInsight | Major Companies- Novartis, Pfizer, and Several Others

DelveInsight's "Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2032" report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Parainfluenza Virus Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key facts of the Parainfluenza Virus Infection Market
• The Parainfluenza Virus Infection market size in the seven major markets was USD 237.22 Million in 2021.
• The total diagnosed prevalent population of Parainfluenza Virus Infection in the 7 major markets was 1,900,310 in 2021. In case of Parainfluenza Virus Infection patients in the United States, the diagnosed prevalent population were found to be 766,630 in 2021, which is anticipated to increase during the forecasted period.
• In Japan, the diagnosed prevalent population of Parainfluenza Virus Infection was found to be 65,378 in 2021.
• Some of the emerging Parainfluenza Virus Infection therapies are DAS181, ALVR-106 and others.
• According to a study titled "Parainfluenza Viruses" done by H. Kelly et al., each HPIV-1 resulted in an estimated 18,000-3,50,000 US children under the age of five. In the United States, up to 6000 children under the age of 18 were hospitalized each year for HPIV-2. It was discovered that young newborns (less than 6 months) are especially prone to HPIV-3 infection.
• Another research, "Epidemiological, Molecular, and Clinical Features of Enterovirus Respiratory Infections in French Children Between 1999 and 2005," by J. Jerome et al., found that 2444 (21%) of 11,509 children tested positive for respiratory viral infections. PIV Type-3 was found to be present in 4 percent of all positive respiratory virus infections.

Request for Sample Report:- https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key benefits of the Parainfluenza Virus Infection Market report:
• The study provides a detailed review of Parainfluenza Virus Infection, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
• Study of the 7MM has offered comprehensive insight into the epidemiology and management of Parainfluenza Virus Infection.
• Furthermore, an all-inclusive description of both present and emerging Parainfluenza Virus Infection treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
• The research includes a full evaluation of the Parainfluenza Virus Infection market, both historical and anticipated, as well as drug outreach in the 7MM population.
• By understanding the trends defining and driving the worldwide Parainfluenza Virus Infection market, the study gives you an advantage when formulating business plans.

Parainfluenza Virus Infection Overview
The Parainfluenza Viruses (PIVs) are non-segmented, negative-strand RNA viruses of the family Paramyxoviridae. The paramyxoviruses include not only the PIVs but also several other important human pathogens transmitted through the respiratory route such as a human respiratory syncytial virus (HRSV), metapneumovirus, measles virus, and mumps virus. Human PIVs (HPIVs) have four serotypes (HPIV 1-4) and are a primary cause of lower respiratory tract (LRT) infection in newborns and children. The HPIVs are easily transferred by direct contact and nasopharyngeal secretions, and virtually all children are infected with HPIV3 by the age of two, and with HPIV1 and HPIV2 by the age of five. Because no anti-PIV vaccinations or medications are available, non-pharmaceutical measures are now the only way of control. The therapy for a Parainfluenza Virus infection is solely symptomatic and supportive. As a result, no drug is licensed for the treatment of the condition, and it is regarded as the disease's primary concern.

Parainfluenza Virus Infection Market
The report's Parainfluenza Virus Infection market outlook assists in developing a detailed understanding of historic, current, and forecasted Parainfluenza Virus Infection market trends by analyzing the impact of current Parainfluenza Virus Infection therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This section examines the Parainfluenza Virus Infection market trend of each marketed drug and late stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders' perspectives. Parainfluenza Virus Infection market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance. According to DelveInsight, the Parainfluenza Virus Infection market in 7MM is expected to undergo significant change between 2019 and 2032.

Learn more by requesting for sample @ https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Parainfluenza Virus Infection Companies
• Novartis
• Ansun Biopharma
• Pfizer
• AlloVir
• Brazion Therapeutics, and Several Others

Know more about the pipeline therapies and recent developments @ https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Parainfluenza Virus Infection Market Report
• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parainfluenza Virus Infection Companies: Novartis (SWX: NOVN), Pfizer (NYSE: PFE), Brazion Therapeutics, Ansun Biopharma, AlloVir (NASDAQ: ALVR), Merck & Co., Inc (NYSE: MRK), GlaxoSmithKline plc (LON: GSK), Boehringer Ingelheim International GmbH, AstraZeneca (LON: AZN), Teva Pharmaceutical Industries Ltd (TLV: TEVA), F. Hoffmann-La Roche Ltd (SWX: ROG), Cipla (NSE: CIPLA), Sanofi (EPA: SAN), Orion Corporation (HEL: ORNBV), CHIESI Farmaceutici S.p.A., and others
• Key Parainfluenza Virus Infection Pipeline Therapies: DAS181, ALVR106, and others
• Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection current marketed and emerging therapies
• Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Parainfluenza Virus Infection Market Access and Reimbursement

Request for a Webex demo of the report @ https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Key Insights
2. Executive Summary of Parainfluenza Virus Infection
3. Competitive Intelligence Analysis for Parainfluenza Virus Infection
4. Parainfluenza Virus Infection: Market Overview at a Glance
5. Parainfluenza Virus Infection: Disease Background and Overview
6. Parainfluenza Virus Infection Patient Journey
7. Parainfluenza Virus Infection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Parainfluenza Virus Infection Unmet Needs
10. Key Endpoints of Parainfluenza Virus Infection Treatment
11. Parainfluenza Virus Infection Marketed Products
12. Parainfluenza Virus Infection Emerging Therapies
13. Parainfluenza Virus Infection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Parainfluenza Virus Infection Market Outlook
16. Access and Reimbursement Overview of Parainfluenza Virus Infection
17. KOL Views
18. Parainfluenza Virus Infection Market Drivers
19. Parainfluenza Virus Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Click here to read more about the report @ https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hpv-Induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.